Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Cytotherapy|October 11, 2015
Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantationHisayoshi Hashimoto, Shigehisa Kitano, Shizuka Yamagata, et al.
Journal for Immunotherapy of Cancer|January 7, 2022
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b studyAkie Kimura Yoshikawa, Kensei Yamaguchi, Kei Muro, et al.
Cancer Immunology Research|May 22, 2014
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomesShigehisa Kitano, Michael A Postow, Carly G K Ziegler, et al.
Oncotarget|December 10, 2017
The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapyHirokazu Shoji, Kohei Tada, Shigehisa Kitano, et al.
Frontiers in Immunology|March 9, 2018
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic LeukemiaCiprian Tomuleasa, Shigeo Fuji, Cristian Berce, et al.
Cancer Science|September 9, 2022
First-in-human study of ONO-4578, an antagonist of prostaglandin E<sub>2</sub> receptor 4, alone and with nivolumab in solid tumorsSatoru Iwasa, Takafumi Koyama, Makoto Nishino, et al.
European Journal of Haematology|September 6, 2019
Association of CD204<sup>+</sup> macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCTAkihisa Kawajiri, Shigehisa Kitano, Akiko Miyagi Maeshima, et al.
BMC Cancer|November 23, 2017
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case reportYukinori Ozaki, Junichi Shindoh, Yuji Miura, et al.
Asia-Pacific Journal of Clinical Oncology|September 5, 2024
Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancerYoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, et al.
Targeted Oncology|March 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric CancerTakeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Cytotherapy|October 11, 2015
Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantationHisayoshi Hashimoto, Shigehisa Kitano, Shizuka Yamagata, et al.
Journal for Immunotherapy of Cancer|January 7, 2022
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b studyAkie Kimura Yoshikawa, Kensei Yamaguchi, Kei Muro, et al.
Cancer Immunology Research|May 22, 2014
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomesShigehisa Kitano, Michael A Postow, Carly G K Ziegler, et al.
Oncotarget|December 10, 2017
The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapyHirokazu Shoji, Kohei Tada, Shigehisa Kitano, et al.
Frontiers in Immunology|March 9, 2018
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic LeukemiaCiprian Tomuleasa, Shigeo Fuji, Cristian Berce, et al.
Cancer Science|September 9, 2022
First-in-human study of ONO-4578, an antagonist of prostaglandin E<sub>2</sub> receptor 4, alone and with nivolumab in solid tumorsSatoru Iwasa, Takafumi Koyama, Makoto Nishino, et al.
European Journal of Haematology|September 6, 2019
Association of CD204<sup>+</sup> macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCTAkihisa Kawajiri, Shigehisa Kitano, Akiko Miyagi Maeshima, et al.
BMC Cancer|November 23, 2017
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case reportYukinori Ozaki, Junichi Shindoh, Yuji Miura, et al.
Asia-Pacific Journal of Clinical Oncology|September 5, 2024
Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancerYoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, et al.
Targeted Oncology|March 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric CancerTakeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka, et al.
Pageof 15